Subscription Status · Aug 24 – Aug 27, 2026 · ₹938–988
The Symbiotec Pharmalab IPO subscription has recorded exceptional investor demand with an overall subscription of 75.05× as of Aug 27, 2026, indicating that investors applied for 75.05 times the number of shares on offer. All investor categories (institutional, HNI, and retail) have participated actively, making this one of the closely watched IPO openings.
Last updated: Aug 27, 2026, 5:12 PM IST
| Category | Shares Offered | Shares Bid For | Times Subscribed |
|---|---|---|---|
|
QIB
Qualified Institutional Buyers
|
3,550,608 | 643,359,195 |
181.20×
|
|
NII
Non-Institutional Investors
|
2,662,955 | 206,509,395 |
77.55×
|
|
bNII
Bids above ₹10L
|
1,775,303 | 155,046,495 |
87.34×
|
|
sNII
Bids below ₹10L
|
887,652 | 51,462,900 |
57.98×
|
|
Retail
Retail Individual Investors
|
6,213,562 | 84,807,780 |
13.65×
|
|
Employees
Employee Category
|
33,408 | 543,915 |
16.28×
|
|
Total
|
12,460,533 | 935,220,285 |
75.05×
|
How subscription built up across investor categories over time
Snapshot of each day's bidding activity
| Category | Offered | Bid For | Times |
|---|---|---|---|
| QIB | 3,550,608 | 1,326,390 | 0.37× |
| NII | 2,662,955 | 2,927,160 | 1.10× |
| bNII | 1,775,303 | 1,451,265 | 0.82× |
| sNII | 887,652 | 1,475,895 | 1.66× |
| Retail | 6,213,562 | 6,247,950 | 1.01× |
| Employees | 33,408 | 55,035 | 1.65× |
| Total | 12,460,533 | 10,556,535 | 0.85× |
| Category | Offered | Bid For | Times |
|---|---|---|---|
| QIB | 3,550,608 | 2,032,740 | 0.57× |
| NII | 2,662,955 | 8,405,430 | 3.16× |
| bNII | 1,775,303 | 4,591,725 | 2.59× |
| sNII | 887,652 | 3,813,705 | 4.30× |
| Retail | 6,213,562 | 13,789,380 | 2.22× |
| Employees | 33,408 | 106,440 | 3.19× |
| Total | 12,460,533 | 24,333,990 | 1.95× |
| Category | Offered | Bid For | Times |
|---|---|---|---|
| QIB | 3,550,608 | 2,213,355 | 0.62× |
| NII | 2,662,955 | 34,207,470 | 12.85× |
| bNII | 1,775,303 | 21,124,395 | 11.90× |
| sNII | 887,652 | 13,083,075 | 14.74× |
| Retail | 6,213,562 | 33,303,450 | 5.36× |
| Employees | 33,408 | 208,275 | 6.23× |
| Total | 12,460,533 | 69,932,550 | 5.61× |
| Category | Offered | Bid For | Times |
|---|---|---|---|
| QIB | 3,550,608 | 643,359,195 | 181.20× |
| NII | 2,662,955 | 206,509,395 | 77.55× |
| bNII | 1,775,303 | 155,046,495 | 87.34× |
| sNII | 887,652 | 51,462,900 | 57.98× |
| Retail | 6,213,562 | 84,807,780 | 13.65× |
| Employees | 33,408 | 543,915 | 16.28× |
| Total | 12,460,533 | 935,220,285 | 75.05× |
As of August 27, 2026, the Symbiotec Pharmalab IPO has been subscribed 75.05 times overall. The IPO is fully subscribed with strong investor demand indicating extremely high interest.
The Symbiotec Pharmalab IPO subscription window was open from August 24, 2026 to August 27, 2026. Investors could apply through their demat account or ASBA facility.
The Symbiotec Pharmalab IPO has a price band of ₹938 to ₹988 per share, with a lot size of 15 shares. Minimum retail investment: ₹14,070 (lower band) or ₹14,820 (upper band).
The QIB category has been subscribed 181.20 times. QIBs were offered 3,550,608 shares. Strong QIB subscription indicates high institutional confidence.
Retail investors subscribed 13.65 times. Retail was offered 6,213,562 shares. High retail subscription reflects strong small-investor interest.
Overall NII: 77.55×. bNII (>₹10L): 87.34×, sNII (<₹10L): 57.98×. NII includes HNIs and corporate entities investing above ₹2 lakh.
Basis of allotment is on August 28, 2026. Check via the registrar's website, MUFG Intime India Pvt.Ltd using your PAN number, application number, or DP/Client ID. You can also check on BSE/NSE websites or through your broker's app.
Symbiotec Pharmalab IPO is expected to list on September 01, 2026. Shares will list on NSE,BSE. Allotted shares are credited to your demat account 1 business day before listing.
A subscription multiple of 75.05× means investors have bid for 75.05 times the total shares available. Since the IPO is oversubscribed, not every applicant will receive shares, allotment happens via lottery (for retail) or proportionately (for other categories). Higher multiples generally reduce allotment probability.
Based on the current retail subscription of 13.65×, the estimated allotment probability for retail investors is Low–Moderate. Lottery-based allotment. Retail allotment in oversubscribed IPOs is done by computerised lottery, each valid application has an equal probability regardless of the number of lots applied for.
You can apply for Symbiotec Pharmalab IPO through: (1) ASBA (Application Supported by Blocked Amount) via your bank's net banking or mobile app, (2) UPI-based application through your broker's app (Zerodha, Groww, Angel One, etc.), or (3) directly via your demat account. The amount is blocked in your account and deducted only upon allotment. Applications were accepted from Aug 24 to Aug 27, 2026.
The grey market premium (GMP) reflects unofficial pre-listing trading sentiment. For the latest Symbiotec Pharmalab IPO GMP data, check the IPORise GMP page. Note: GMP is unofficial, speculative, and not a guaranteed indicator of listing price. Use it only as a sentiment signal alongside official subscription data.
New to reading subscription numbers? Read our guide on IPO subscription explained.
Subscription Opens Done
Aug 24, 2026Subscription Closes Done
Aug 27, 2026Basis of Allotment Done
Aug 28, 2026Listing on NSE,BSE Done
Sep 01, 2026Lottery-based allotment. Based on retail subscription of 13.65×.
Retail allotment in oversubscribed IPOs is done by computerised lottery, each valid application has equal odds regardless of lot size applied.
Share Subscription Card
Download a branded image to share on WhatsApp, Twitter, or Telegram
Higher subscription = lower allotment probability. Progress bars compare each category relative to the highest-subscribed category.